New MRI dye could spot hidden prostate cancer cells
NCT ID NCT04261777
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested whether an iron-based contrast agent called Ferumoxtran-10 (Ferrotran®) could improve MRI scans to find prostate cancer that has spread to lymph nodes. The study involved 172 men with newly diagnosed prostate cancer at intermediate to high risk of spread. Each patient received the contrast agent before MRI, and the results were compared to standard MRI and tissue samples after surgery. The trial was terminated early, so final conclusions are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ferumoxtran-10 (Ferrotran®), an iron-based contrast agent given as an intravenous infusion before MRI
What this could lead to
If successful, this could provide a more accurate, non-invasive way to detect cancer spread to lymph nodes in prostate cancer patients, potentially reducing unnecessary surgeries.
What could go wrong
The trial was terminated early, so results may be incomplete. The approach is still experimental and may not prove better than current methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Canisius-Wilhelmina Ziekenhuis Nijmegen
Nijmegen, 6532, Netherlands
-
Charité - Universitätsklinikum Berlin
Berlin, State of Berlin, 10117, Germany
-
Inselspital-Universitätsspital Bern
Bern, 3010, Switzerland
-
Nederlands Kanker Instituut Antoni van Leeuwenhoek
Amsterdam, 1006, Netherlands
-
Radboud University Medical Center
Nijmegen, 6525, Netherlands
-
Universitair Ziekenhuis Ghent
Ghent, 9000, Belgium
-
Universitätsklinikum Bonn
Bonn, 53127, Germany
-
Universitätsklinikum Carl Gustav Carus
Dresden, 01307, Germany
-
Universitätsklinikum Düsseldorf
Düsseldorf, 40225, Germany
-
Universitätsklinikum Essen
Essen, 45147, Germany
-
Universitätsklinikum Köln
Cologne, 50937, Germany
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Schleswig-Holstein Lübeck
Lübeck, 23538, Germany
-
Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Universität Heidelberg
Mannheim, 68167, Germany
-
Vivantes Klinikum Am Urban
Berlin, 10967, Germany